Why GLP-1 Trials Use Different Endpoints
Weight, A1c, cardiovascular events — what a trial measures shapes what its result means.
When you read that a GLP-1 drug “worked” in a trial, the first question worth asking is: worked at what? A study designed to measure blood-sugar control answers a different question than one designed to measure weight loss, and both differ from one built to count heart attacks and strokes. The endpoint a trial chooses is not a technicality. It defines what the result can honestly claim.
The three families of endpoints
Most GLP-1 and dual-agonist trials are built around one of three primary measures.
- Glycemic endpoints — usually change in HbA1c, the marker of average blood sugar over months. These were the original endpoints for diabetes drugs and remain the regulatory backbone for diabetes approval.
- Weight endpoints — percent change in body weight, the focus of obesity trials. A drug can post impressive weight numbers without that automatically translating to other health gains.
- Cardiovascular outcome endpoints — counts of “hard” events like heart attack, stroke, or cardiovascular death, typically grouped into a composite measure. These trials are larger, longer, and far more expensive, because events take years to accumulate.
A surrogate endpoint like A1c or weight tells you the drug moves a number. An outcomes endpoint tells you the drug changes what happens to people. They are not interchangeable.
Why the distinction matters
A surrogate endpoint is a stand-in for what we actually care about. Lower A1c is meaningful because, over time, it usually tracks with fewer complications. But “usually” is doing real work in that sentence. Drug history is full of agents that improved a surrogate marker while failing, or even harming, on outcomes. That is why cardiovascular outcome trials became the gold standard: they test whether the surrogate improvement actually buys you a longer, healthier life.
How to read a headline responsibly
When a result crosses your feed, it helps to mentally tag it:
- Was the primary endpoint a surrogate (weight, A1c) or an outcome (events, mortality)?
- Was the comparison against placebo or against another active drug?
- Was the population studied similar to the person being prescribed the drug?
The newer GLP-1 and dual agonists have increasingly strong outcome data behind some uses, which is genuinely notable. But not every approved use rests on outcomes evidence, and the marketing rarely makes the distinction clear.
The bottom line
The endpoint is the question. A weight-loss number and a reduced-stroke number are both valuable, but they answer different things, and conflating them overstates what we know. The data suggests reading any GLP-1 claim by first identifying what was measured — and treating surrogate wins as promising rather than proven until outcomes confirm them.
This is sample content created during site scaffolding. Replace with reviewed, fully-cited editorial before launch.